GlobeNewswire: Arcturus Therapeutics, Inc. Contains the last 10 of 92 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T18:50:32ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2020/09/08/2090113/0/en/Arcturus-Therapeutics-to-Present-at-Upcoming-Investor-and-Scientific-Conferences.html?f=22&fvtc=4&fvtv=38938Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences2020-09-08T12:30:00Z<![CDATA[SAN DIEGO, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Company will be presenting at upcoming investor and scientific conferences virtually:]]>https://www.globenewswire.com/news-release/2020/09/04/2089182/0/en/Arcturus-Therapeutics-Announces-Preclinical-Publication-of-its-COVID-19-Vaccine-Candidate.html?f=22&fvtc=4&fvtv=38938Arcturus Therapeutics Announces Preclinical Publication of its COVID-19 Vaccine Candidate 2020-09-04T14:31:46Z<![CDATA[Encouraging preclinical results demonstrate a strong antibody and cellular immune response and 100% protection against SARS-CoV-2 infection following a single vaccination]]>https://www.globenewswire.com/news-release/2020/08/18/2080000/0/en/Arcturus-Therapeutics-Executes-Definitive-Supply-Agreement-with-the-Israeli-Ministry-of-Health.html?f=22&fvtc=4&fvtv=38938Arcturus Therapeutics Executes Definitive Supply Agreement with the Israeli Ministry of Health2020-08-18T13:00:00Z<![CDATA[SAN DIEGO, Aug. 18, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that it has executed the definitive supply agreement provided for in the previously announced binding term sheet agreement with the Israeli Ministry of Health, to supply COVID-19 STARR™ mRNA vaccine candidate (ARCT-021). Delivery to Israel of doses of Arcturus’ COVID-19 vaccine candidate is contingent upon achievement of near term clinical and regulatory milestones.]]>https://www.globenewswire.com/news-release/2020/08/11/2076339/0/en/Arcturus-Therapeutics-Announces-that-it-has-Initiated-Dosing-of-its-COVID-19-STARR-mRNA-Vaccine-Candidate-LUNAR-COV19-ARCT-021-in-a-Phase-1-2-study.html?f=22&fvtc=4&fvtv=38938Arcturus Therapeutics Announces that it has Initiated Dosing of its COVID-19 STARR™ mRNA Vaccine Candidate, LUNAR-COV19 (ARCT-021) in a Phase 1/2 study2020-08-11T12:00:57Z<![CDATA[Potential for highly differentiated COVID-19 vaccine profile with a single administration, at a low dose]]>https://www.globenewswire.com/news-release/2020/08/10/2075908/0/en/Arcturus-Therapeutics-Announces-Second-Quarter-2020-Financial-Results-and-Provides-a-Corporate-Update.html?f=22&fvtc=4&fvtv=38938Arcturus Therapeutics Announces Second Quarter 2020 Financial Results and Provides a Corporate Update2020-08-10T20:01:00Z<![CDATA[COVID-19 STARR™ mRNA vaccine candidate, ARCT-021 (LUNAR-COV19) has initiated Phase 1/2 clinical study with Duke-NUS Medical School; Dosing anticipated imminently, initial data expected Q4]]>https://www.globenewswire.com/news-release/2020/08/06/2074223/0/en/Arcturus-Therapeutics-Appoints-Lance-Kurata-as-Chief-Legal-Officer.html?f=22&fvtc=4&fvtv=38938Arcturus Therapeutics Appoints Lance Kurata as Chief Legal Officer2020-08-06T12:30:00Z<![CDATA[Nationally recognized leader in corporate life sciences transactions Nationally recognized leader in corporate life sciences transactions]]>https://www.globenewswire.com/news-release/2020/08/04/2072496/0/en/Arcturus-Therapeutics-to-Report-Second-Quarter-2020-Financial-Results-and-Provide-Corporate-Update-on-August-10-2020.html?f=22&fvtc=4&fvtv=38938Arcturus Therapeutics to Report Second Quarter 2020 Financial Results and Provide Corporate Update on August 10, 20202020-08-04T12:30:00Z<![CDATA[SAN DIEGO, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that it will release its financial results for the quarter ended June 30, 2020 after the market close on August 10 and will also provide a corporate overview and financial results by hosting a conference call and webcast at 4:30 pm Eastern Time on Monday, Aug 10, 2020.]]>https://www.globenewswire.com/news-release/2020/07/31/2071317/0/en/Arcturus-Therapeutics-Announces-Closing-of-Public-Offering-and-Full-Exercise-of-Underwriters-Option-to-Purchase-Additional-Shares.html?f=22&fvtc=4&fvtv=38938Arcturus Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares2020-07-31T20:01:00Z<![CDATA[SAN DIEGO, July 31, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, announced the closing on July 31, 2020 of its previously announced underwritten public offering of 3,753,773 shares of its common stock at a public offering price of $53.00 per share, which included the exercise in full by the underwriters of their option to purchase up to an additional 489,622 shares of common stock at the public offering price, less underwriting discounts and commissions. Arcturus received total gross proceeds from the offering (before deducting the underwriting discounts and offering expenses) of approximately $200 million. The Company intends to use the net proceeds of the offering to develop, test and manufacture the Company’s LUNAR-COV19 vaccine candidate and to continue clinical development of LUNAR-OTC; to advance the Company’s LUNAR-CF, LUNAR-CV and LUNAR-FLU preclinical programs into clinical development; to fund early research and development of novel and proprietary RNA medicines; and for general corporate and working capital purposes.]]>https://www.globenewswire.com/news-release/2020/07/29/2069135/0/en/Arcturus-Therapeutics-Announces-Pricing-of-173-0-Million-Public-Offering-of-Common-Stock.html?f=22&fvtc=4&fvtv=38938Arcturus Therapeutics Announces Pricing of $173.0 Million Public Offering of Common Stock2020-07-29T04:30:00Z<![CDATA[SAN DIEGO, July 29, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, NASDAQ: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced the pricing of an underwritten public offering of 3,264,151 shares of its common stock at a public offering price of $53.00 per share. The gross proceeds of the offering to the Company are expected to be approximately $173.0 million, before deducting the underwriting discounts and commissions and other estimated offering expenses. In addition, the Company granted the underwriters a thirty-day option to purchase up to an additional 489,622 shares of common stock at the public offering price, less underwriting discounts and commissions.]]>https://www.globenewswire.com/news-release/2020/07/28/2068991/0/en/Arcturus-Therapeutics-Announces-Proposed-Public-Offering-of-Common-Stock.html?f=22&fvtc=4&fvtv=38938Arcturus Therapeutics Announces Proposed Public Offering of Common Stock2020-07-28T20:01:00Z<![CDATA[SAN DIEGO, July 28, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, NASDAQ: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the shares to be sold in the offering will be offered by the Company. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. In addition, the Company intends to grant the underwriters a thirty-day option to purchase up to an additional 15 percent of shares of its common stock offered in the public offering.]]>